Biotechnology and Pharmaceuticals

With the spread of modern molecular and cell technologies, biotechnology and pharmaceuticals are currently experiencing a change that is leading to completely new possibilities for advanced therapeutic approaches. Novel cell therapies, for example based on stem cells, require efficient, automated and at the same time adaptive production processes. In addition, there are regulatory requirements that oblige manufacturing companies to implement complex control and quality assurance measures.

The Fraunhofer IPT researches concepts with which manufacturing companies in the biotechnology and pharmaceutical industries can prepare themselves for the challenges of the future: We automate laboratory processes in order to increase throughput and quality and reduce costs. We also network systems and investigate how process data from production facilities can be used to optimize production systems and products.

Our research areas


Bio Lab of the Future

Modern laboratories are becoming more and more intelligent and relieve laboratory staff. Through automated systems, smart devices and networking of laboratory equipment, we increase the efficiency of your laboratory.


Pharma 4.0

Digitization, networking and automation enable tighter monitoring of production processes in the pharmaceutical industry and assist in meeting the regulatory requirements for traceability and anti-counterfeiting.


Next Generation Therapies

New therapeutic approaches using the latest research findings offer hope for people with previously incurable diseases. We develop production processes for innovative medical applications.

International Collaborations

We regularly exchange views on new developments with other research institutions – especially with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME in Aachen and the Fraunhofer Center or Manufacturing Innovation CMI in Boston.



Automated, bioreactor-based production of stem cells for medical purposes

Project duration: 2016/1/1 to 2018/12/31

Funding: EU – Horizon 2020



Standardized and integrated procedure for personalized stem cell-based drug prediction using reprogrammed blood cells

Project duration: 2017/7/1 to 2020/6/30

Funding: EU – EFRE.NRW